Selection of high-efficacy and low-toxicity drugs is key to improving the efficacy of chemotherapy for solid tumors.Because of tumor heterogeneity and ethnic/individual differences,the efficiency and toxicity of chemotherapy drugs vary across individuals.Since standard chemotherapy regimens developed based on population data can not completely meet clinical needs,increasing attention has been directed towards individualized chemotherapy based on drug genetics and/or genomics testing.In this paper,we review the advances in identifying predictive markers for response to fluoropyrimidine-based chemotherapy for colorectal cancer.

1 病例报告 女性,57岁,于2009年12月无明显诱因下出现左下肢疼痛伴腰背疼痛,2010年于外院行腰椎CT检查示:L3-4,L4-5,L5-S1椎间盘突出.予针灸等对症治疗后症状无改善,疼痛逐渐加重,只能平卧无法下床活动,体重下降10余公斤.

To explore the efficacy and toxicity-related markers of specific chemotherapy drugs and markers can help clinical selection of high efficient and low toxic chemotheraputic drugs and their combination to achieve the goal of individual therapy is the research focus.This paper aims to review UGT1A1 polymorphism and the efficacy and safety of irinotecan.